Patients with cystic fibrosis often reduce or discontinue respiratory cotherapies after starting CFTR modulators without affecting clinical status.

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

Sionna Therapeutics targets cystic fibrosis with novel CFTR/NBD1 stabilization; key 2026 readouts and cash runway to 2028.

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.

Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...

-Interim results of largest real-world study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) showed sustained improvement in lung function, reduction ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and superior in reducing sweat chloride compared to TRIKAFTA - - Approximately 3,800 people in Canada are now eligible for ...

For decades, lung disease has been the most visible and life-threatening part of cystic fibrosis. People might picture ...

Please provide your email address to receive an email when new articles are posted on . Lung function in pregnant women with cystic fibrosis not using CFTR modulators went down after pregnancy. There ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...